Bimatoprost currently the only company which has an FDA-approved Generic Bimatoprost Ophthalmic Solution, 0.03% available on the market.Bimatoprost Ophthalmic Solution, 0.03% is indicated to treat elevated intraocular pressure in patients with open-angle glaucoma, or for people who have ocular hypertension.
Contact lenses should be removed prior to instillation of bimatoprost ophthalmic solution, 0.03% and may be reinserted 15 minutes following its administration.Do not allow the tip of the dispensing container to contact the eye surrounding structures, fingers, or any other surface in order to avoid contamination of the solution by common bacteria known to cause ocular infections.
Bimatoprost serum on 0.03% has been reported to cause increased brown pigmentation of the iris, which is likely to be permanent. Also, most frequently reported changes have been darkening of the periorbital tissue (eyelid) and eyelashes, which may be reversible after discontinuation of bimatoprost ophthalmic solution, 0.03%. While treatment with bimatoprost ophthalmic solution, 0.03% can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly.
These changes include increased length, thickness, and number of lashes. These changes may result in a disparity between eyes in length, thickness, pigmentation, number of eyelashes or vellus hairs, and/or direction of eyelash growth. Eyelash changes are usually reversible upon discontinuation of treatment. Eyelash changes are usually reversible upon discontinuation of treatment.